Bliss GVS Pharma Ltd.
Snapshot View

View in App

Prices View details >>

71.20 +0.67 ▲1.0%

31 March 2023, 04:01:00 PM
Volume: 7,775

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.blissgvs.com
Market Cap 742.09 Cr.
Enterprise Value(EV) 695.65 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 8.37 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 8.51 Trailing Twelve Months Ending 2022-12
Industry PE 32.41 Trailing Twelve Months Ending 2022-12
Book Value / Share 84.82 Trailing Twelve Months Ending 2022-12
Price to Book Value 0.84 Calculated using Price: 71.20
Dividend Yield 0.70 Period Ending 2022-03
No. of Shares Subscribed 10.42 Cr. 104,152,672 Shares
FaceValue 1
Company Profile
It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company's most unique product is ‘Today Vaginal Contraceptive', a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.95%
1 Week
-0.48%
1 Month
-10.50%
3 Month
-1.86%
6 Month
-6.75%
1 Year
-7.47%
2 Year
-27.86%
5 Year
-63.55%
10 Year
+166.67%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 15.17 19.74 26.73 25.06 17.34 21.43 13.79 9.64 2.88
Return on Capital Employed (%) 20.56 23.57 32.07 31.06 24.61 26.58 17.02 12.49 6.37
Return on Assets (%) 6.46 9.01 13.04 11.88 9.42 14.35 9.86 7.03 2.12

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 287 337 413 487 536 646 736 808 819 854
Non Curr. Liab. 96 68 50 33 13 38 46 45 29 43
Curr. Liab. 308 243 379 437 299 207 231 204 233 172
Minority Int. 10 15 33 66 11 14 15 20 28 32
Equity & Liab. 700 662 874 1,023 860 905 1,027 1,077 1,109 1,101
Non Curr. Assets 230 245 291 457 170 211 257 312 333 383
Curr. Assets 469 417 583 566 690 693 770 765 776 718
Misc. Exp. not W/O 1 0
Total Assets 700 662 874 1,023 860 905 1,027 1,077 1,109 1,101

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 345 407 547 798 815 899 689 577 747 734
Other Income 28 20 24 13 27 38 39 22 31 27
Total Income 373 427 571 811 841 936 728 599 779 761
Total Expenditure -273 -304 -391 -596 -618 -741 -566 -471 -629 -603
PBIDT 99 124 180 215 224 195 163 129 150 158
Interest -18 -16 -19 -20 -23 -4 -8 -7 -5 -7
Depreciation -11 -11 -13 -20 -21 -9 -13 -17 -17 -18
Taxation -30 -35 -48 -63 -57 -55 -34 -30 -31 -37
Exceptional Items -34 -13 -74
PAT 41 61 100 113 89 127 95 74 23 97
Minority Interest 0 -1 -18 -31 -30 -3 2 -5 -8 -10
Share Associate
Other Related Items
Consolidated Net Profit 41 60 82 82 59 124 97 68 15 87
Adjusted EPS 4 6 8 8 6 12 9 7 1 8

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 7 41 38 113 289 18 40 47 64 135
Cash Fr. Inv. -124 -11 -29 -50 -231 50 -74 -48 -47 -93
Cash Fr. Finan. 110 -8 -42 -40 -10 -76 17 -6 -21 -24
Net Change -8 22 -33 23 48 -8 -17 -8 -4 19
Cash & Cash Eqvt 50 50 5 28 47 37 15 15 13 22

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 33.31 33.31 33.24 33.19 33.14 33.14 34.51 34.55 34.46
Public 66.69 66.69 66.76 66.81 66.86 66.86 65.49 65.45 65.54
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Fri, 31 Mar 2023
Closure of Trading Window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 and in accordance with the Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited will remain closed for Insiders Designated Persons and their immediate relatives of the Company with effect from Saturday April 01 2023 until 48 hours after the announcement of the Audited Financial results of the Company for the quarter and year ended March 31 2023. The Board meeting for the declaration of Audited Financial Results for the quarter and year ended March 31 2023 shall be intimated later.Accordingly Insiders Designated Persons and their immediate relatives are advised not to trade (buy or sell or pledge etc.) in the securities/shares of the Company during the aforesaid period of closure of the Trading Window.
Thu, 23 Mar 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited have received a request to issue of duplicate share certificate consequent to loss of share certificate from the shareholder.
Sat, 18 Mar 2023
Intimation About Completion Of US FDA Inspection At Plot 11 Of The Company
This is to inform you that the United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) and Good Manufacturing Practice (GMP) inspection at the Companys manufacturing unit at Plot No. 11 Survey No. 38/1 Dewan Udyog Nagar Aliyali Village Palghar 401404 Maharashtra from Monday March 13 2023 to Friday March 17 2023. After the inspection the US FDA issued a Form 483 with 3 minor observations. The observations are procedural in nature. None of the observations relate to data integrity. The Company shall prepare detailed response to the observations which will be submitted to the US FDA within the stipulated timelines. The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Technical Scans View Details >>

Fri, 31 Mar 2023
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Below Last Month Low Close Below Last Month Low

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 235,878.62 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. 76,960.86 4,624.15 +1.3%
Divi's Laboratories Ltd. 75,014.78 2,826.00 +0.3%
Cipla Ltd. 72,696.02 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. 61,962.56 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. 52,030.91 1,543.40 +0.2%
Zydus Lifesciences Ltd. 49,749.83 491.00 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 56.00 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 21.13 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-12 31.30 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-12 27.55 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 81.03 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.86 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-12 24.11 491.00 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.26 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.50 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-12 6.03 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-12 3.20 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.04 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.19 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.88 491.00 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 0.04 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 491.00 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 13.10 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 491.00 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 13.10 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 491.00 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 21,763.34 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 491.00 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 983.10 -0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,624.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,826.00 +0.3%
Cipla Ltd. Consolidated 2022-03 2,559.47 900.65 +1.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,309.40 -1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,543.40 +0.2%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 491.00 +0.1%

FAQ's On Bliss GVS Pharma Ltd.

What is Bliss GVS Pharma share price?
Can I buy Bliss GVS Pharma shares now?
What is the Dividend Yield of Bliss GVS Pharma?
What is the Market Cap of Bliss GVS Pharma?
What are the key metrics to analyse Bliss GVS Pharma?
What is the 52 Week High and Low of Bliss GVS Pharma?
What is the trend of Bliss GVS Pharma share price?